- Home
- OMF vs NUVL Comparison
OMF vs NUVL Comparison
Compare OMF & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMF
- NUVL
- Stock Information
- Founded
- OMF 1920
- NUVL 2017
- Country
- OMF United States
- NUVL United States
- Employees
- OMF N/A
- NUVL N/A
- Industry
- OMF Finance: Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OMF Finance
- NUVL Health Care
- Exchange
- OMF Nasdaq
- NUVL Nasdaq
- Market Cap
- OMF 5.3B
- NUVL 5.6B
- IPO Year
- OMF 2013
- NUVL 2021
- Fundamental
- Price
- OMF $48.98
- NUVL $69.85
- Analyst Decision
- OMF Buy
- NUVL Strong Buy
- Analyst Count
- OMF 13
- NUVL 8
- Target Price
- OMF $57.00
- NUVL $115.50
- AVG Volume (30 Days)
- OMF 1.2M
- NUVL 625.4K
- Earning Date
- OMF 04-29-2025
- NUVL 05-08-2025
- Dividend Yield
- OMF 8.49%
- NUVL N/A
- EPS Growth
- OMF N/A
- NUVL N/A
- EPS
- OMF 4.73
- NUVL N/A
- Revenue
- OMF $2,583,000,000.00
- NUVL N/A
- Revenue This Year
- OMF $76.29
- NUVL N/A
- Revenue Next Year
- OMF $8.77
- NUVL N/A
- P/E Ratio
- OMF $10.36
- NUVL N/A
- Revenue Growth
- OMF 0.94
- NUVL N/A
- 52 Week Low
- OMF $38.00
- NUVL $55.54
- 52 Week High
- OMF $58.90
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OMF 54.33
- NUVL 46.22
- Support Level
- OMF $47.58
- NUVL $63.56
- Resistance Level
- OMF $50.68
- NUVL $78.97
- Average True Range (ATR)
- OMF 1.60
- NUVL 3.46
- MACD
- OMF 0.39
- NUVL -0.38
- Stochastic Oscillator
- OMF 73.64
- NUVL 40.84
About OMF OneMain Holdings Inc.
OneMain Holdings Inc is engaged in nonprime consumer finance companies in the United States and is one of only a few companies in the consumer installment lending industry. It formed after a transaction brought together two branch-based consumer finance companies with complementary strategies and locations. Its services include providing personal loan products, offering credit and noncredit insurance, servicing loans, pursuing strategic acquisitions and dispositions of assets and businesses, and on occasion, establishing joint ventures or forming strategic alliances. The company's one reportable segment is consumer and insurance. In addition to hundreds of branches, the company also has an online business. The main source of revenue is net interest income.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.